InterMune to Present at Cowen Health Care Conference
... BRISBANE, Calif., March 13 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Cowen and Company 29th Annua...InterMune Reports Results from Triple Combination Study of ITMN-191
...gin in Q2 2009 - - Conference call today at 8:30 a.m. EST - BRISBANE, Calif., Jan. 12 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today reported top-line results from all six completed dosage cohorts of its Phase 1b clinical trial of ITMN-191 (R7227) in combination with standar...InterMune to Present at Thomas Weisel Partners Healthcare Conference
... BRISBANE, Calif., Aug. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the Thomas Weisel Partners Healthcare Conference in ...InterMune to Present at the 2008 Wachovia Healthcare Conference
... BRISBANE, Calif., Jan. 23 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Steven Porter, M.D., Ph.D., Chief Medical Officer of InterMune, will present at the 2008 Wachovia Healthcare Conference in Bost...HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes
...ics Inc RESP 157248157.2 Theravance Inc THRX 212837798.5 Intermune Inc itmn 296874543.2 Sepracor Inc. SEPR 385036542.3 Nektar Therapeutics NKTR 1272671080 Encys...InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
... BRISBANE, Calif., Feb. 2 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that it will report results from its Phase 3 CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis (IPF) prior to market ...InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
... BRISBANE, Calif., Dec. 10 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today said that it will report top-line results in January 2009 from its Phase 1b clinical trial of protease inhibitor ITMN-191 (R7227) in combinati...InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
...s Shionogi Phase 3 results on pirfenidone - BRISBANE, Calif., May 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that its program for the development of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) has received "Fast Trac...InterMune Announces Progress on Pirfenidone in IPF
...ne study now available on ATS website - BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that it will initiate an open-label roll-over study to evaluate the long-term safety of pirfenidone in patients with idiopathic pulm...InterMune to Present at Canaccord Adams Conference
... BRISBANE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Canaccord Adams 29th Annual Global...InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
... BRISBANE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced results from operations for the second quarter and six months ended June 30, 2009. InterMune reported a net loss for the second q...InterMune to Release Second Quarter Financial Results on August 6
... BRISBANE, Calif., July 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) announced today that it will release second quarter 2009 financial results on Thursday, August 6, 2009 at 4:00 p.m. Eastern time. A live conference...InterMune to Present at Goldman Sachs Healthcare Conference
... BRISBANE, Calif., June 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Daniel Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Goldman Sachs 30th Annual Globa...InterMune Reports First Quarter 2009 Financial Results and Business Highlights
... data from 14-day triple combination study of ITMN-191 in HCV - BRISBANE, Calif. , April 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced results from operations for the first quarter ended March 31, 2009. InterMune reported a net loss for the first quarter of 2009 o...InterMune to Release First Quarter Financial Results on April 30
... BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) announced today that it will release first quarter 2009 financial results on Thursday, April 30, 2009 at 4:00 p.m. Eastern time. A live conference ...InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
... -- Conference Call and Webcast Scheduled -- BRISBANE, Calif., April 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that InterMune and Pharmasset, Inc. will host a live webcast of a discussion of the INFORM-1 results from the EASL conference on Sat...InterMune to Present at Canaccord Adams Hepatitis C Conference
... BRISBANE, Calif., April 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Steven B. Porter, M.D., Ph.D., Chief Medical Officer of InterMune, will present at the Canaccord Adams Hepatitis C Conference o...